FINWIRES · TerminalLIVE
FINWIRES

SHE:000963

6 stories mentioning SHE:000963

Every FINWIRES story that references SHE:000963, newest first.

Asia

Chinese Drug Regulator Accepts Huadong Medicine's Application for Facial Filler's New Indication

China's National Medical Products Administration accepted Huadong Medicine's (SHE:000963) application to add a new indication for a facial filler, according to a Shenzhen bourse filing on Wednesday.The Chinese drugmaker applied for the Ellansé S Injectable Polycaprolactone Microsphere Facial Filler to be used as an implant into the forehead to improve moderate to severe forehead contour defects.The company's shares jumped 5% at the close.

SHE:000963
Asia

Huadong Medicine's Unit Gets Nod to Trial HDM2017 for Injection

Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of HDM2017 for injection, according to a Shenzhen bourse filing on Thursday.The drug is used in combination with Fruquintinib for the treatment of advanced colorectal cancer.

SHE:000963
Asia

Huadong Medicine's Attributable Profit Jumps 9.6% in Q1; Shares Rise 3%

Huadong Medicine's (SHE:000963) attributable profit rose 9.6% to 1.00 billion yuan in the first quarter from 914.7 million yuan in the year-ago period, according to a Friday filing with the Shenzhen bourse.Earnings per share at the drug maker increased to 0.5715 yuan from 0.5213 yuan in the prior-year period.Operating income grew 4.2% year over year to 11.2 billion yuan from 10.7 billion yuan.Shares increased 3% during afternoon trading on Friday.

SHE:000963
Asia

Huadong Medicine's Attributable Profit Slips 2.8% in 2025

Huadong Medicine's (SHE:000963) attributable profit fell 2.8% year over year to 3.41 billion yuan in 2025, according to a Friday filing with the Shanghai bourse.Operating revenue jumped 4.1% year over year to 43.6 billion yuan.Shares increased 3% during afternoon trading on Friday.

SHE:000963
Asia

Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%

Huadong Medicine (SHE:000963) has obtained a medical device registration certificate from China's National Medical Products Administration for a new variant of its Ellansé aesthetics product, according to a Shenzhen Stock Exchange filing on Friday.The newly approved Ellansé M-type is a Class III medical device for injection containing polycaprolactone microspheres for facial filling. It has been approved for market launch, said Huadong.The M-type variant is designed for the temporal region. Huadong has already been marketing its Ellansé S-type product in China since August 2021.Shares of the company rose 4% in recent trade.

SHE:000963
Asia

Huadong Medicine's Weight-Loss Drug Marketing Application Accepted in China

Huadong Medicine (SHE:000963) said China's drug administrator accepted its marketing application for semaglutide injection.The drug is used for long-term weight management in obese or overweight adults, according to a Wednesday filing with the Shenzhen bourse.Shares of the drugmaker closed 2% higher Wednesday.

SHE:000963